The shares are listed on the Nasdaq Global Market

Davis Polk advised the underwriters in connection with the initial public offering of 6,250,000 shares of common stock of Metagenomi, Inc. at $15.00 per share for total gross proceeds of approximately $93.75 million. The common stock is listed on the Nasdaq Global Market under the symbol “MGX.”

Metagenomi, Inc., is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Yasin Keshvargar and associates Caroline G. Armstrong and Sierra M. Acosta. Partner David R. Bauer and associates Adrian Rabin and Austin Fuss provided intellectual property advice. The tax team included partner Kara L. Mungovan and associate Charles Collier. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post